Anacura
Evergem, Oost-Vlaanderen, Belgium, Europe
Overview
Anacura is an independent analytical centre of excellence offering a broad range of high-quality pharmaceutical analyses (Anacura Life Sciences) and medical analyses (Anacura Medical). Anacura Life Sciences provides analytical services to pharma, biopharma and cell based therapy developers. Anabiotec, their GMP compliant platform, is your reliable partner for stability and release testing of pharmaceutical and biotechnological products in all phases of development. They deliver analytical techniques for identity, purity, quantity, quality and potency testing of pharmaceutical and biological products according to the ICH guidelines. Their experts have extensive experience in method development and validation. Their analytical expertise in combination with their operational performance helps you save time and shortens time to market. Complemented with solid advice and efficient project management, they anticipate changing priorities, safeguarding your milestones and timing.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 1
- Active investors
- 1
Sector focus
- Biotechnology
- Life Science
- Pharmaceutical
Investment portfolio
- Sightera
Led · Seed · Jul 2026
Sightera develops an AI-native drug discovery platform that trains generative models on proprietary datasets derived from patient-derived biological samples and organoid preclinical models. By centering human disease biology—particularly samples from individuals with advanced, therapy-resistant disease—the company aims to design small molecules based on observed biological responses rather than solely chemical properties. Its stated therapeutic focuses are oncology and fibrosis, with a lead molecular glue oncology programme moving toward preclinical candidate selection. Sightera is a spin-off of the University of Antwerp and Antwerp University Hospital (UZA) and will use its recent funding to expand its research, AI and data science teams and to strengthen strategic partnerships with pharma and biotech companies. The company plans to scale its platform and accelerate translation of its pipeline using the new capital.
Team
Vicky Gheerardijn
Project Manager Pharmaceuticals